Probiotics
Our probiotics have been developed using a multi-disciplinary approach based on state-of-the-art screening methodology.
More than 2000 potential candidate bacterial strains were put through a range of screening criteria in order to select the most suitable strains: Lactobacullus rhamnosus HN001 (trademarked as DR20TM) and Bifidobacterium lactis HN019 (trademarked as DR10TM ).
DR10TM and DR20TM have been studied extensively in vitro, and in vivo to establish beneficial effects1,2 and safety. Compelling evidence to demonstrate their immune protective properties has been obtained and published in peer reviewed journals.1 Human clinical trials, including rigorous double-blind placebo-controlled protocols, have been employed to establish benefits in different population groups, especially with regards to effects on immune modulation.
Dietary intervention studies3,4 in humans have also demonstrated that both DR10TM and DR20TM not only survive passage through the human gut but also increase the levels of other beneficial bacteria in the gastrointestinal tract. Beneficial effects associated with desirable intestinal microbial populations are well documented.5
Tangible clinical benefits around supporting a healthy immune system have been demonstrated for DR10TM (consumed with galacto-oligosaccharides) in a large, year-long clinical trial involving 634 one to three year old children around supporting a healthy immune system.6
Delivery of probiotics, ensuring consumers receive adequate doses of robust live bacteria, is essential to realising the full potential of probiotics. The development of a range of applications and consumer-friendly product formats is one of our core strengths.
DR10TM and DR20TM have been successfully incorporated into powders, yoghurts, drinking yoghurt, cheeses, fruit juices, snacks and beverages around the world.
1 Gopal et al Development and commercialisation of Fonterra probiotic strains Australian Journal of Dairy Technology (2005) 60 174-183
2 Sander M.E Summary of probiotic activities of Bifidobacterium lactis HN019. Journal of Clinical Gasterloenterology (2006) 40:776-783
3 Gopal et al Effect of consumption of Bifidobacterium lactis HN019 and galacto-oligosaccharides on microflora of gastrointestinal tract in human subjects Nutrition Research ( 2003)23;1313-1328
4 Tannock et al Analysis of fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Applied and Environmental Microbiology (2000) 66:2578-2588
5 Xu J and G. Horothy Symbionts Proceeding of National Academy of Science USA (2003) 18:10452-10459
6 Sazawal et al Efficacy of milk fortified with a probiotics Bifidobacterium lactis (DR10TM) and a prebiotic galacto-oligosaccharide in prevention of morbidity and on nutritional status. Asia Pacific Journal of Clinical Nutrition (2004) 13:28
7 Sistek et al Is the effect of probiotics on atopic dermatitis confined to food sensitised children? Clinical and Experimental Allergy 36:629-633.
